Failed NDI Notifications Suggest Futility Of Current US Position On Cannabinoids In Supplements
Executive Summary
FDA's evaluation of NDI notifications for cannabinoids currently is pointless, say industry stakeholders asking for a rule exempting hemp-derived cannabinoids from the agency’s prohibition against using in dietary supplements any ingredient studied or approved for use as a drug.
You may also be interested in...
In Second Term At Helm, Would Califf Steer US FDA On Supplement Market Regulation Changes?
CRN and NPA are receptive to former FDA Commissioner Robert Califf’s potential return to the post. NPA says his previous comments on FDA’s authority is a good sign he may help act on supplement industry issues stalled within the agency in recent years.
Court Suggests Critics Ask Congress To Change FDA's GRAS Rule – Same For NDI Notifications?
Federal judge suggests consumer health and environmental advocacy groups made strong arguments about potential for unsafe ingredients in foods available in the US through the self-GRAS process, but FDA adopted and exercises the rule entirely in line with congressional intent of the authorizing legislation.
BioMedican Pitches Cannabinoid Biosynthesis Investing; Cultivated Market Sprouts More Deals
BioMedican needs support until it can begin generating revenues and conduct an IPO. Businesses already marketing cannabinoid supplements receive more funding, or in some cases are acquired, as well as expand distribution.